Craig Spellman, DO
Endocrinology, Diabetes & Metabolism · Odessa, TXNPI 1174587935
Payments from drug & device makers
Across 261 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$881
- Amgen$832
- Lilly USA, LLC$679
- Boehringer Ingelheim$378
- Radius Health, Inc.$299
- Tandem Diabetes Care, Inc.$211
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,728100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $881 |
| Amgen(2 entities) | 45 | $832 |
| Lilly USA, LLC | 37 | $679 |
| Boehringer Ingelheim | 17 | $378 |
| Radius Health, Inc. | 17 | $299 |
| Tandem Diabetes Care, Inc. | 10 | $211 |
| Ultragenyx Pharmaceutical Inc. | 9 | $194 |
| Insulet Corporation | 7 | $140 |
| Abbott | 6 | $137 |
| Dexcom, Inc. | 7 | $122 |
| Corcept Therapeutics | 5 | $100 |
| Xeris Pharmaceuticals, Inc. | 5 | $98 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Amryt Pharma Holdings Ltd | 4 | $90 |
| Medtronic(2 entities) | 4 | $68 |
| AstraZeneca(2 entities) | 3 | $62 |
| Mannkind Corporation | 2 | $48 |
| Ascendis Pharma Endocrinology Inc | 2 | $48 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Pfizer | 2 | $38 |
| Soleno Therapeutics, Inc. | 1 | $33 |
| BETA Bionics, Inc. | 2 | $29 |
| Echosens North America, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
How this compares
$4,728 in reported general payments places this provider in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 55 | $66,592 |
| OzempicSemaglutide | 33 | $43,489 |
| MounjaroTirzepatide | 24 | $28,403 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $22,210 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $11,276 |
| Novolog FlexpenInsulin Aspart | 33 | $9,505 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $9,441 |
| JanuviaSitagliptin Phosphate | 11 | $5,749 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,130 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $4,987 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,721 |
| EntrestoSacubitril/Valsartan | 12 | $3,651 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $2,786 |
| SynthroidLevothyroxine Sodium | 14 | $849 |
| Metformin Hcl ErMetformin Hcl | 51 | $815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $378 | $66,59255 claims |
| Novo NordiskOzempic | $881 | $43,48933 claims |
| Lilly USA, LLCMounjaro | $679 | $28,40324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Odessa
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.